Main Uses and Therapeutic Scope

Furazolidon is an antimicrobial and antiprotozoal agent used primarily to manage infections within the gastrointestinal tract. It belongs to the nitrofuran class of drugs and is characterized by its dual action against a variety of pathogens, including certain bacteria and protozoa.

Bacterial Infections

The primary application of Furazolidon is the treatment of bacterial diarrhea and enteritis. It is effective against several gram-positive and gram-negative organisms that compromise intestinal health. By interfering with the DNA processes and enzyme systems of these microbes, the medication helps to resolve symptoms associated with food poisoning and bacterial overgrowth.

Protozoal Infections

In addition to its antibacterial properties, Furazolidon is utilized in the management of specific protozoal conditions. It is frequently indicated for:

• Giardiasis: An intestinal infection caused by the Giardia lamblia parasite, which can lead to malabsorption and chronic diarrhea.
• Cholera: It may be used as an adjunct therapy in treating the severe diarrhea caused by Vibrio cholerae.

Mechanisms and Benefits

Furazolidon acts locally within the gut, which allows for targeted action at the site of infection. This localized approach is beneficial for several reasons:

• Broad Spectrum of Activity: It addresses a wide range of gastrointestinal pathogens simultaneously, which is useful when the specific cause of the infection is not immediately identified.
• Reduction of Inflammation: By eliminating the underlying infectious agents, the medication helps reduce mucosal inflammation in the intestines, leading to the restoration of normal bowel function.
• Limited Systemic Absorption: Because the drug is not extensively absorbed into the bloodstream, its primary effects are concentrated in the digestive system, minimizing influence on other body systems.

Key Benefits in Patient Care

The use of Furazolidon in a clinical context focuses on stabilizing the patient’s gastrointestinal health and preventing the complications of prolonged infection, such as dehydration and nutrient loss. By effectively neutralizing pathogens, it supports the body's natural recovery process and helps return the intestinal flora to a balanced state.

Regulatory References

1. National Cancer Institute Drug Dictionary

Eligibility Map: Who can and cannot use Furazolidone — official regulatory information

The eligibility profile for Furazolidone is defined by specific population restrictions and contraindications documented in regulatory labeling.

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label):	Adults and pediatric patients aged 1 month and older have established use documented in labeling.
Populations for whom use is contraindicated:	Patients with known hypersensitivity to Furazolidone or other nitrofurans. Patients receiving Monoamine Oxidase (MAO) Inhibitor drugs.
Age-related eligibility rules:	The medicine is contraindicated in infants under 1 month of age due to the risk of hemolytic anemia. Safety and effectiveness have not been specifically studied in the geriatric population.
Condition-specific eligibility rules:	Use requires caution in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.
Pregnancy and lactation eligibility status:	Safety has not been established in pregnant women or breastfeeding women. Use is only permitted when clearly needed and with caution.

---

Eligibility Classifications (High-Level)

Classification	Official Regulatory Statement
Eligibility severity classification:	Categories include Contraindicated (e.g., Infants <1 month, MAOI users) and Use with Caution (e.g., G6PD deficiency).

---

Resulting eligibility structure

Official eligibility statements:

• The medicine is contraindicated in infants under 1 month of age.
• Concomitant use with Monoamine Oxidase (MAO) Inhibitor drugs is contraindicated.
• Use requires caution in patients with G6PD deficiency, and the drug should be discontinued if hemolytic anemia occurs.

Connection to the overall eligibility profile: Regulatory documents establish absolute contraindications based on age, prior drug use, and allergy, formalizing non-eligibility for specific groups. Conditional eligibility is defined by explicit labeling requiring caution for populations with metabolic vulnerability (G6PD deficiency). The profile also notes populations where safety data is formally not established, such as pregnant and breastfeeding women.

The official interaction profile for Furazolidone is defined by its inhibitory effect on key metabolic enzymes, which results in several mandated restrictions. This medicinal product acts as an irreversible inhibitor of Monoamine Oxidase (MAO), which is the high-level mechanistic basis for multiple required contraindications and constraints in government labeling.

Co-administration with other Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the cumulative risk of severe pressor reactions, including hypertensive crisis. Serotonergic agents, such as SSRIs and tricyclic antidepressants, are also restricted combinations associated with the risk of inducing Serotonin Syndrome.

A separate official interaction arises from the product's effect on Alcohol Dehydrogenase, which renders the use of alcohol (ethanol) contraindicated during therapy and for at least four days following the final dose, due to the potential for a disulfiram-like reaction. Furthermore, the MAO inhibition necessitates the strict prohibition of consuming tyramine-containing foods (e.g., aged cheeses, fermented products). This dietary restriction must be maintained for a period of at least two weeks after therapy is complete to allow for enzyme regeneration. Population-specific caution is also noted in official documents for patients with Glucose-6-Phosphate Dehydrogenase (G-6-PD) Deficiency due to the potential for hemolytic anemia.

u1f52c How Furazolidone Works: Mechanism of Action

Furazolidone acts through two primary, chemically-driven mechanisms: the irreversible damage to target microbes and a secondary, host-related enzyme inhibition.

---

Microbial Prodrug Activation and Cellular Shutdown

This domain covers the process by which the drug, in its administered form, is inactive and requires a unique step for function. Susceptible pathogens (bacteria and protozoa) possess specialized nitroreductase enzymes that chemically reduce the Furazolidone molecule. This transformation generates highly toxic, reactive intermediates that immediately cause non-specific, irreversible damage to the microbe's vital components. The resulting molecular cascade induces structural failure in systems, including the microbial DNA synthesis and energy metabolism, resulting in pathogen cell death.

---

Host Monoamine Oxidase (MAO) Inhibition

This distinct domain involves an interaction with a regulatory enzyme in the host's body. Furazolidone non-selectively inhibits Monoamine Oxidase (MAO), the enzyme responsible for metabolizing various amines. This inhibition limits the host's ability to break down these amines, which can lead to an accumulation of adrenergic mediators (like norepinephrine) in the systemic circulation. This MAO inhibition is associated with an accumulation of adrenergic mediators, influencing sympathetic pathway dynamics.

Official Administration Guidelines for Furazolidon

Route of Administration: Oral (by mouth).

Frequency and Timing:

Furazolidon is typically taken four times a day (QID). It may be consumed with food to minimize the potential for stomach upset.

Official Dosing Schedule

Patient Group	Condition	Dose	Duration
Adults	Cholera or Bacterial Diarrhea	100 milligrams (mg)	5 to 7 days
Adults	Giardiasis	100 mg	7 to 10 days
Children (1 month and over)	Cholera or Bacterial Diarrhea	1.25 mg/kg body weight (in four divided doses)	5 to 7 days
Children (1 month and over)	Giardiasis	1.25 to 2 mg/kg body weight (in four divided doses)	7 to 10 days

Age-Specific Use Rules:

Use in infants younger than 1 month of age is not recommended.

Preparation Requirements:

For the oral suspension, an accurate, specially marked measuring spoon or device must be used for dosing; a standard household teaspoon is not a sufficient measuring tool.

Missed-Dose Instructions:

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped, and the regular dosing schedule should be resumed. Do not double doses to compensate for a missed one.

Procedural Condition:

The medicine must be taken for the full prescribed length of treatment to ensure complete infection clearance, even if symptoms begin to improve quickly.

Furazolidon: Recent Clinical Evidence

Research regarding furazolidone primarily focuses on its established applications and emerging patterns of antimicrobial resistance. As a nitrofuran antibiotic, its mechanism of action involves interaction with bacterial DNA, leading to a disruption of metabolic processes, which is the basis for its use against certain susceptible bacteria and protozoa.

Clinical Efficacy and Indications

Clinical data support furazolidone's use in treating specific gastrointestinal infections, including cholera and diarrhea caused by Giardia lamblia (giardiasis) and Escherichia coli (E. coli). Efficacy studies, primarily conducted in regions where these infections are endemic, evaluate the drug based on clinical cure rates and microbiological eradication compared to placebo or other established therapies.

Resistance and Safety Profile

Recent surveillance studies have noted a geographic variation in the susceptibility of target pathogens to furazolidone. This observed antimicrobial resistance remains a key factor in clinical decision-making, influencing its role as a first-line or alternative treatment.

Safety reviews highlight that furazolidone is associated with gastrointestinal side effects, such as nausea and vomiting. A critical consideration noted in clinical guidelines is the drug's activity as a monoamine oxidase inhibitor (MAOI), requiring caution due to potential drug-drug and drug-food interactions. Studies on its long-term use are generally limited, focusing instead on short, defined courses of treatment for acute conditions.

Key Studies & References WHO Model List of Essential Medicines

How to Store and Dispose of Furazolidone

The storage and disposal of Furazolidone are subject to specific requirements outlined in regulatory labeling to maintain the product's stability and ensure responsible handling.

Storage & Handling Requirement	Official Regulatory Instruction
Temperature & Environment	Store at room temperature, away from heat, moisture, and direct light. Do not freeze the medicine.
Container & Child Safety	Keep the product in a closed container and securely out of the reach of children. Store the product locked up.
Stability Notes	Crystals are documented to darken under strong light. Do not keep or use medicine that is outdated or no longer needed.

The disposal of unused or expired Furazolidone must adhere to official protocols. The first recommended option is utilizing a drug take-back program or event. If not available, most medicines can be safely disposed of in the household trash by removing them from their original containers, mixing with an undesirable substance (like coffee grounds or kitty litter), and sealing the mixture in a bag before discarding. Environmental regulations further require that the product not be allowed to enter sewers or waterways and that disposal complies with local and national regulations.